Jeff Yass’s Cue Biopharma CUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,003
Closed -$326K – 13647
2026
Q2
$347K Buy
11,003
+10,183
+1,242% +$230K ﹤0.01% 10734
2026
Q1
$5.66K Sell
820
-4,808
-85% -$44.9K ﹤0.01% 12979
2025
Q4
$51.6K Buy
5,628
+79
+1% +$1.45K ﹤0.01% 11740
2025
Q3
$120K Buy
5,549
+408
+8% +$9.6K ﹤0.01% 11456
2025
Q2
$105K Buy
+5,141
New +$110K ﹤0.01% 11770
2025
Q1
– Sell
-442
Closed -$14.5K – 12614
2024
Q4
$14.5K Buy
+442
New +$16.6K ﹤0.01% 11952
2024
Q3
– Sell
-3,991
Closed -$148K – 12137
2024
Q2
$148K Buy
3,991
+2,869
+256% +$142K ﹤0.01% 10705
2024
Q1
$63.6K Buy
1,122
+659
+142% +$46.5K ﹤0.01% 11458
2023
Q4
$36.7K Sell
463
-1,962
-81% -$140K ﹤0.01% 11827
2023
Q3
$167K Buy
2,425
+236
+11% +$23K ﹤0.01% 10436
2023
Q2
$240K Sell
2,189
-2,229
-50% -$262K ﹤0.01% 9901
2023
Q1
$473K Buy
+4,418
New +$421K ﹤0.01% 8700
2022
Q4
– Sell
-952
Closed -$87.1K – 12602
2022
Q3
$64K Sell
952
-4,548
-83% -$391K ﹤0.01% 12044
2022
Q2
$411K Buy
5,500
+3,143
+133% +$368K ﹤0.01% 8753
2022
Q1
$345K Buy
2,357
+774
+49% +$164K ﹤0.01% 9920
2021
Q4
$537K Buy
1,583
+623
+65% +$241K ﹤0.01% 8992
2021
Q3
$420K Sell
960
-544
-36% -$190K ﹤0.01% 9821
2021
Q2
$526K Sell
1,504
-378
-20% -$147K ﹤0.01% 9457
2021
Q1
$689K Buy
1,882
+1,107
+143% +$456K ﹤0.01% 8703
2020
Q4
$291K Sell
775
-238
-23% -$95.1K ﹤0.01% 9317
2020
Q3
$458K Buy
1,013
+261
+35% +$150K ﹤0.01% 7858
2020
Q2
$553K Buy
+752
New +$545K ﹤0.01% 7158

Other funds holding CUE

Jeff Yass's CUE Position: Q3 2026 in Review

Jeff Yass sold out of Cue Biopharma (CUE) in Q3 2026, closing a stake of 11,003 shares — an estimated $326K sold.

Jeff Yass first reported a position in CUE in Q2 2020 and held it in 22 quarters. The position peaked at $689K in Q1 2021. 58 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

  • Jeff Yass reported no remaining Cue Biopharma position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 11,003 Cue Biopharma shares in Q3 2026, an estimated $326K.
  • Jeff Yass first reported a position in Cue Biopharma in Q2 2020 and held it in 22 quarters.
  • Jeff Yass's Cue Biopharma position peaked at $689K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.